http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-102004019736-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb66d9373d09efad73c142762f6dfb00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate | 2004-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2ed2ed793330685a87b55c380fcbe36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_117276acedb58bcd8c773f3bbc8334d1 |
| publicationDate | 2005-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-102004019736-A1 |
| titleOfInvention | Use of the CGRP antagonist 1 [N2 [3,5 dibromo-N - [[4 (3,4-dihydro-2 (1H) oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] - L-lysyl] -4- (4-pyridinyl) piperazine in combination with (+) - N-methyl-3- (1-naphthyloxy) -3- (2-thienyl) propanamine for the treatment of migraine |
| abstract | ThenThe present invention relates to a method of treatment ornpreventionnfrom headache, migrainenor cluster headache, the method being co-administeredna therapeutically effective amount of the CGRP antagonist (A) or anphysiologically compatiblenSalt thereof and a therapeutically effective amount of the selectivenSerotonin reuptake inhibitor (B) or a physiologically acceptablenSalt thereof includes, as well as the corresponding pharmaceuticalnCompositions and their preparation. |
| priorityDate | 2004-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.